Renal denervation is a minimally invasive method of treating hypertension. The renal denervation procedure lowers blood pressure and reduces hyperactive signals by ablation with ultrasonography or radiofrequency on nerves in the renal artery. Through nerves, the kidneys, heart, and brain collaborate to regulate blood pressure. Innovative medicine known as renal denervation can replace or lessen the requirement for high blood pressure medication.
The market worth of renal denervation in 2021 was USD 219.49 million, and it will be worth USD 4743.13 million by 2030, growing at a 40.7% CAGR during the forecast period.
A major factor accelerating market expansion is the large rise in the prevalence of lifestyle disorders like hypertension, which are brought on by an increase in sedentary and stressful lifestyles, alcoholic and tobacco use, poor eating habits, and an escalating senior population.
The primary drivers driving the growth of the global market include an increase in the prevalence of hypertension, and blood pressure, changing lifestyles, and improved healthcare infrastructure in emerging nations, such as micro-infusion for renal denervation systems.
The risk of heart disease & stroke, the two main causes of mortality worldwide, and complications of high blood pressure, including stroke death and heart failure, are expected to drive the expansion of the target market.
Micro-infusion is one of the alternatives and more advanced technologies for renal denervation systems. The availability of other advanced technologies, demanding regulatory body approvals, poor reimbursement, and a shortage of qualified healthcare personnel are thus key market limitations.
The treatment used to treat hypertension is less invasive. A device known as an ultrasound-based renal denervation device sends an ultrasound into the renal artery wall to interfere with nerve impulse transmission and lower blood pressure. This procedure boosts effectiveness, laying the groundwork for the renal denervation market’s future.
On the basis of technology, the market is segmented into micro infusion, radiofrequency ablation, and ultrasound. The radiofrequency ablation segment led the market, with a revenue share of around 78.15%. There are many benefits to radiofrequency ablation, including safety and time effectiveness. Additionally, Radiofrequency Ablation is a one-time treatment for hypertension that lasts for at least two years. All of these elements effectively fuel the segment’s expansion. According to a study, radiofrequency ablation is between 70 and 80% successful in treating persons with severe nerve blocks.
Regionally, in 2020, Europe ruled the market with the largest share of around 65.58%. This is partly due to increased government financing for expanding R&D initiatives and the region’s steadily rising hypertension cases. Over 40% of Europeans over the age of 25 have hypertension, and 10% of those have medication-resistant hypertension, according to a study (RHT). In 2020, Germany had the highest prevalence of hypertension (about 55%), followed by Finland (almost 49%), Spain (around 47%), England (roughly 42%), Sweden (roughly 38%), and Italy (roughly 38%).
In addition, due to rapidly rising cases of diabetes, hypertension, obesity, and other lifestyle disorders, the Asia Pacific (APAC) area will experience the fastest growth rate during the projected period. According to the Saw Swee Hock School of Public Health, 113.9 million individuals in China, or around 11.6% of the world’s adult population, have diabetes, making up about 60% of all people with the disease.
- Johnson & Johnson
- Cardiotonic Ltd
- Ablative Solutions, Inc
- Abbott Laboratories
- Boston Scientific Corporation
- ReCor Medical, Inc
- Medtronic plc
- Mercator MedSystems, Inc
- Renal Dynamics Limited
- Terumo Corporation
The market worth of renal denervation in 2021 was USD 219.49 million, and it will be worth USD 4743.13 million by 2030, growing at a 40.7% CAGR during the forecast period. The rise in cases of hypertension, the rising use of radiofrequency ablation and endovascular catheters, the steady rise in cases of CHF (congestive heart failure), and atrial fibrillation are the main reasons driving the growth of the global renal denervation market.